DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors

Eligibility Criteria

• * Adults aged ≥ 18 years or acceptable age according to local regulations at the time of voluntarily signing informed consent.
• * At least one measurable lesion as assessed by the Investigator according to RECIST v1.1 criteria.
• * Has a life expectancy of ≥ 3 months.
• * Has an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-1
• * Has adequate organ function within 7 days prior to enrollment/randomization,
• * Has adequate treatment washout period prior to the first dose of trial treatment.
• * For HCC patients: Histological/cytological confirmed diagnosis of HCC or clinically confirmed diagnosis of HCC; Has a Child-Pugh class A liver score.
• * For CC patients: Has persistent, recurrent or metastatic cervical cancer with squamous cell, adenocarcinoma, or adenosquamous histology
• * For Melanoma patients: Histologically or cytologically confirmed diagnosis of unresectable Stage III or metastatic melanoma.
• * For PROC patients (Cohort A): Participants must have a confirmed diagnosis of OC, primary peritoneal cancer, or fallopian tube cancer, all of which with high-grade serous histology. Patients must have platinum-resistant disease.
• * For HNSCC patients: Histologically or cytologically confirmed recurrent (recurrent disease that is not amendable to curative treatment with local/ or systemic therapies)/ (disseminated) HNSCC of the oral cavity, oropharynx, hypopharynx, and larynx that is considered incurable by local therapies.
• * For NSCLC patients: Pathologically documented Stage IIIB or IIIC NSCLC not amenable for radical surgery or definitive chemoradiation or Stage IV NSQ NSCLC. Not harboring an EGFR-sensitizing mutation or ALK gene rearrangements or other onco-driver gene mutations
• * 1\. Prior treatment with B7H3 targeted therapy.
• * Prior treatment with antibody-drug conjugate with topoisomerase inhibitor.
• * Is a candidate to locoregional treatment with potential to induce complete or near complete response and prolonged tumor control, per investigator's assessment.
• * Has an uncontrolled concomitant or intercurrent illness, that in the opinion of the investigator, contra-indicates trial participation, limits compliance with trial procedures or substantially increases the risk of incurring AEs.
• * Has uncontrolled or significant cardiovascular disease. Has clinically uncontrolled pleural effusion, ascites or pericardial effusion requiring drainage, peritoneal shunt, or cell-free concentrated ascites reinfusion therapy.
• * Has a history of (non-infectious) ILD/pneumonitis.
• * Any autoimmune, connective tissue or inflammatory disorders.
• * Has spinal cord compression or clinically active central nervous system (CNS) metastases.
• * Has unresolved toxicities from previous anticancer therapy, defined as toxicities (other than alopecia) not yet resolved to Grade ≤1 or baseline.